Physician profile
John W Lee
NPI 1316938657
$2,382.27
in general payments reported to CMS, 2019-2025
16 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2021: $1,303 · 2022: $18.88 · 2023: $125 · 2024: $130 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $932.82 | 2021 | |
| Siemens Medical Solutions USA, INC. | $174.33 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $170.37 | 2019-2021 | |
| Elekta, INC. | $151.00 | 2025 | |
| Visionrt, INC. | $146.04 | 2019 | |
| Portola Pharmaceuticals, LLC | $125.99 | 2019 | |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Puma Biotechnology, INC. | $124.97 | 2021 | |
| Daiichi Sankyo INC. | $120.21 | 2021 | |
| Biogen, INC. | $93.46 | 2019 | |
| Reflexion Medical, INC. | $67.67 | 2024 | Reflexion Medical Radiotherapy System |
| Angiodynamics, INC. | $54.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.71 | 2024 | Libtayo |
| Coherus Oncology, INC. | $25.05 | 2024 | |
| Genzyme Corporation | $18.88 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.